Aberrant expression of T cell and B cell markers in myelocyte/monocyte/histiocyte-derived lymphoma and leukemia cells. Is the infrequent expression of T/B cell markers sufficient to establish a lymphoid origin for Hodgkin's Reed-Sternberg cells?
- PMID: 2492402
- PMCID: PMC1879540
Aberrant expression of T cell and B cell markers in myelocyte/monocyte/histiocyte-derived lymphoma and leukemia cells. Is the infrequent expression of T/B cell markers sufficient to establish a lymphoid origin for Hodgkin's Reed-Sternberg cells?
Abstract
Most Hodgkin's mononuclear cells and Reed-Sternberg (H-RS) cells are characterized by the expression of the antigen CD30, but not of T or B cell markers. A few H-RS cells, however, may express a limited number of T or B cell markers. Whether this expression is sufficient to allow the conclusion that H-RS cells are derived from T and/or B cells has been debated vigorously. The present study examined whether CD30 and aberrant T and B cell markers are expressed in cell lines that are well documented as being derived from the granulocyte/monocyte/histiocyte lineage. These cells included HL-60, KG-1, ML-1, THP-1, and U-937. Four other cell lines derived from patients with leukemias/lymphomas of monocytic or granulocytic origins also were studied. These cells included BV173, CML-Brown, CTV-2, and SU-DHL-1. If aberrant expression is detected, by analogy one may expect that rare T or B cell marker expression may occur in H-RS cells, because abundant evidence has indicated that H-RS cells may be related to cells in histiocyte lineage. In all nine of the cell lines studied, it was confirmed that numerous monocyte/granulocyte markers were expressed. The marker expression was enhanced after cells were induced to differentiate with phorbol ester (TPA) and tumor necrosis factor (TNF). It was noted that several T and B cell markers also were expressed by these cells. Unlike the expression of monocyte/granulocyte markers, the expression of T or B cell markers was not affected, or only minimally affected, by treatment of the cells with TPA or TNF. Five of the cell lines (BV173, CML-Brown, CTV-2, SU-DHL-1, and THP-1) were shown to be CD30-positive. In CTV-2 and BV173, the expression of CD30 was greatly increased after induction with phorbol ester or TNF. Based on these studies, the following conclusions were reached: 1) The expression of aberrant B or T cell markers is not an uncommon finding in granulocyte/monocyte/histiocyte-related neoplastic cells. 2) The expression of granulocyte/monocyte markers in these cells is related to the state of cell differentiation, whereas the expression of T or B cell markers is not. 3) CD30 is not necessarily a proliferation-related antigen, and its expression is not a sole property of T or B cells, but can be present in granulocyte/monocyte/histiocyte-related cells.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Phenotypes and phorbol ester-induced differentiation of human histiocytic lymphoma cell lines (U-937 and SU-DHL-1) and Reed-Sternberg cells.Am J Pathol. 1986 Feb;122(2):223-30. Am J Pathol. 1986. PMID: 3511721 Free PMC article.
-
Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia. 1994 Dec;8(12):2083-94. Leukemia. 1994. PMID: 7528856
-
CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.Am J Pathol. 1996 Aug;149(2):469-81. Am J Pathol. 1996. PMID: 8701986 Free PMC article.
-
Hodgkin's disease, mixed cellularity type, with a B-cell immunophenotype. Report of a case and literature review.Arch Pathol Lab Med. 1995 May;119(5):474-9. Arch Pathol Lab Med. 1995. PMID: 7538289 Review.
-
CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.Leuk Lymphoma. 1996 Feb;20(5-6):397-409. doi: 10.3109/10428199609052421. Leuk Lymphoma. 1996. PMID: 8833395 Review.
Cited by
-
Optimization of Biomimetic, Leukocyte-Mimicking Nanovesicles for Drug Delivery Against Colorectal Cancer Using a Design of Experiment Approach.Front Bioeng Biotechnol. 2022 Jun 8;10:883034. doi: 10.3389/fbioe.2022.883034. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35757799 Free PMC article.
-
A monocyte/macrophage antigen recognized by the four antibodies GHI/61, Ber-MAC3, Ki-M8 and SM4.Immunology. 1992 Apr;75(4):588-95. Immunology. 1992. PMID: 1592433 Free PMC article.
-
Lymphocyte functional antigens stabilize agglutination between Reed-Sternberg cells and T cells, but are not responsible for homotypic binding of Hodgkin's Reed-Sternberg cells.Am J Pathol. 1990 Sep;137(3):563-74. Am J Pathol. 1990. PMID: 1698024 Free PMC article.
-
Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2.Am J Pathol. 1989 Oct;135(4):735-45. Am J Pathol. 1989. PMID: 2801887 Free PMC article.
-
Cultured Reed-Sternberg cells HDLM-1 and KM-H2 can be induced to become histiocytelike cells. H-RS cells are not derived from lymphocytes.Am J Pathol. 1990 Aug;137(2):353-67. Am J Pathol. 1990. PMID: 2167011 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical